BioCentury | Apr 6, 2015
Company News

Hyperion Therapeutics Inc, Horizon Pharma deal

...cycle disorders (UCD): Ravicti glycerol phenylbutyrate and Buphenyl sodium phenylbutyrate. Combined sales of Ravicti and Buphenyl...
BioCentury | Mar 31, 2015
Company News

Horizon buying Hyperion for $1.1B

...cycle disorders (UCD): Ravicti glycerol phenylbutyrate and Buphenyl sodium phenylbutyrate. Combined sales of Ravicti and Buphenyl...
BioCentury | Jun 10, 2013
Company News

Hyperion, Valeant Pharmaceuticals deal

...Hyperion completed the acquisition of worldwide rights to Buphenyl sodium phenylbutyrate from Valeant's Ucyclyd Pharma Inc...
BioCentury | May 13, 2013
Company News

Hyperion, Valeant Pharmaceuticals deal

...an amended 2007 deal with Valeant's Medicis Pharmaceutical Corp. subsidiary to acquire worldwide rights to Buphenyl...
...retain rights to Ammonul for $32 million. If Valeant retains Ammonul, Hyperion's upfront payment for Buphenyl...
...treat the latter indication. GT4P is a pro-drug of phenylbutyrate. Valeant acquired Medicis in 2012. Buphenyl...
BioCentury | Apr 2, 2012
Company News

Hyperion, Medicis deal

...also amended a 2007 deal to give Hyperion an option to acquire worldwide rights to Buphenyl...
...Phase II testing to treat cirrhosis and episodic hepatic encephalopathy, with data expected this quarter. Buphenyl...
BioCentury | Jan 3, 2011
Emerging Company Profile

Hyperion: Building a better mop

...Santel, Buphenyl acts as a "mop to soak up the waste nitrogen in the body." Buphenyl...
...each 0.5 gram tablet of Buphenyl contains 62 mg of sodium, and each dose of Buphenyl...
...subsidiary. The 2007 deal also includes U.S. co-promotion rights for Buphenyl. The ability to co-promote Buphenyl...
BioCentury | Nov 8, 2010
Finance

Regulatory milestones

...Therapeutics Inc. said glycerol phenylbutyrate ( HPN-100 ) met the primary endpoint of non-inferiority to Buphenyl...
BioCentury | Nov 8, 2010
Clinical News

Glycerol phenylbutyrate: Phase III data

...trial in 45 patients showed that thrice-daily HPN-100 met the primary endpoint of non-inferiority to Buphenyl...
...on the last day of each 2-week treatment period. Specifically, ammonia levels for HPN-100 and Buphenyl...
...respectively. Additionally, there was no significant difference in peak plasma concentration (Cmax) between HPN-100 and Buphenyl...
BioCentury | Nov 2, 2010
Clinical News

Hyperion's HPN-100 meets Phase III endpoint

...Francisco, Calif.) said glycerol phenylbutyrate ( HPN-100 ) met the primary endpoint of non-inferiority to Buphenyl...
...Phase III trial to treat urea cycle disorders (UCD). Specifically, ammonia levels for HPN-100 and Buphenyl...
...Hyperion rights to develop HPN-100 for UCD and hepatic encephalopathy, and U.S. co-promotion rights for Buphenyl...
BioCentury | Oct 25, 2010
Clinical News

Glycerol phenylbutyrate regulatory update

...rights to develop glycerold phenylbutyrate for UCD and hepatic encephalopathy, and U.S. co-promotion rights for Buphenyl...
Items per page:
1 - 10 of 25